Fennec Pharmaceuticals (TSE:FRX) Sets New 1-Year High – Time to Buy?

Posted by Trevor Kearing on Jun 23rd, 2026

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s share price hit a new 52-week high on Tuesday . The company traded as high as C$14.50 and last traded at C$14.50, with a volume of 984 shares changing hands. The stock had previously closed at C$12.82.

Fennec Pharmaceuticals Price Performance

The company has a market capitalization of C$520.36 million, a PE ratio of -51.66 and a beta of 3.52. The business has a 50-day moving average of C$11.32 and a 200 day moving average of C$10.73.

Insider Activity at Fennec Pharmaceuticals

In related news, Director Chris Anigeron Rallis sold 8,346 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of C$9.67, for a total value of C$80,705.82. Following the completion of the transaction, the director directly owned 61,314 shares of the company’s stock, valued at approximately C$592,906.38. This trade represents a 11.98% decrease in their ownership of the stock. Also, Director Rostislav Christov Raykov sold 9,747 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of C$13.23, for a total transaction of C$128,952.81. Following the completion of the sale, the director owned 2,746,104 shares in the company, valued at C$36,330,955.92. This represents a 0.35% decrease in their position. 16.20% of the stock is owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.